SciBase Holding AB (publ) (SCIB.ST)
SEK 0.37
(-6.03%)
SEK 0.37
(-6.03%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -27.32 Million SEK | -155.13% |
| 2022 | -10.71 Million SEK | 82.93% |
| 2021 | -62.74 Million SEK | -58.82% |
| 2020 | -39.5 Million SEK | -89.16% |
| 2019 | -20.88 Million SEK | 69.06% |
| 2018 | -67.51 Million SEK | 38.63% |
| 2017 | -110.01 Million SEK | -29.5% |
| 2016 | -84.95 Million SEK | 36.48% |
| 2015 | -133.73 Million SEK | -385.15% |
| 2014 | -27.56 Million SEK | 12.77% |
| 2013 | -31.6 Million SEK | -78.37% |
| 2012 | -17.71 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -40.42 Million SEK | -141.25% |
| 2024 Q1 | -16.75 Million SEK | 38.67% |
| 2023 Q4 | -27.32 Million SEK | 42.74% |
| 2023 Q1 | -9.82 Million SEK | 8.26% |
| 2023 Q3 | -47.72 Million SEK | 28.72% |
| 2023 FY | -27.32 Million SEK | -155.13% |
| 2023 Q2 | -66.95 Million SEK | -581.46% |
| 2022 Q1 | -52.73 Million SEK | 15.95% |
| 2022 Q3 | -33.36 Million SEK | 22.96% |
| 2022 FY | -10.71 Million SEK | 82.93% |
| 2022 Q4 | -10.71 Million SEK | 67.9% |
| 2022 Q2 | -43.3 Million SEK | 17.88% |
| 2021 Q2 | -86.66 Million SEK | -175.97% |
| 2021 Q4 | -62.74 Million SEK | 18.85% |
| 2021 Q3 | -77.32 Million SEK | 10.78% |
| 2021 Q1 | -31.4 Million SEK | 20.51% |
| 2021 FY | -62.74 Million SEK | -58.82% |
| 2020 Q3 | -19.56 Million SEK | 29.77% |
| 2020 Q4 | -39.5 Million SEK | -101.92% |
| 2020 Q1 | -14.95 Million SEK | 28.4% |
| 2020 FY | -39.5 Million SEK | -89.16% |
| 2020 Q2 | -27.86 Million SEK | -86.31% |
| 2019 Q2 | -46.77 Million SEK | 19.44% |
| 2019 FY | -20.88 Million SEK | 69.06% |
| 2019 Q4 | -20.88 Million SEK | 41.85% |
| 2019 Q3 | -35.91 Million SEK | 23.21% |
| 2019 Q1 | -58.05 Million SEK | 14.01% |
| 2018 FY | -67.51 Million SEK | 38.63% |
| 2018 Q1 | -95.54 Million SEK | 13.16% |
| 2018 Q2 | -85.23 Million SEK | 10.79% |
| 2018 Q3 | -77.55 Million SEK | 9.01% |
| 2018 Q4 | -67.51 Million SEK | 12.94% |
| 2017 Q4 | -110.01 Million SEK | -115.94% |
| 2017 FY | -110.01 Million SEK | -29.5% |
| 2017 Q3 | -50.94 Million SEK | 16.44% |
| 2017 Q2 | -60.97 Million SEK | 16.04% |
| 2017 Q1 | -72.62 Million SEK | 14.51% |
| 2016 Q1 | -122.24 Million SEK | 8.6% |
| 2016 Q3 | -98.27 Million SEK | 9.66% |
| 2016 Q2 | -108.78 Million SEK | 11.01% |
| 2016 Q4 | -84.95 Million SEK | 13.55% |
| 2016 FY | -84.95 Million SEK | 36.48% |
| 2015 FY | -133.73 Million SEK | -385.15% |
| 2015 Q2 | -165.59 Million SEK | -856.48% |
| 2015 Q3 | -147.66 Million SEK | 10.83% |
| 2015 Q4 | -133.73 Million SEK | 9.43% |
| 2015 Q1 | -17.31 Million SEK | 37.19% |
| 2014 FY | -27.56 Million SEK | 12.77% |
| 2014 Q4 | -27.56 Million SEK | 0.0% |
| 2014 Q1 | 31.86 Million SEK | 0.0% |
| 2013 FY | -31.6 Million SEK | -78.37% |
| 2012 FY | -17.71 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Acarix AB (publ) | -35.14 Million SEK | 22.262% |
| ADDvise Group AB (publ) | 1.22 Billion SEK | 102.227% |
| ADDvise Group AB (publ) | 1.22 Billion SEK | 102.227% |
| Arcoma AB | -1.12 Million SEK | -2322.34% |
| Bactiguard Holding AB (publ) | 109.88 Million SEK | 124.867% |
| BICO Group AB (publ) | 927.9 Million SEK | 102.945% |
| Boule Diagnostics AB (publ) | 128.8 Million SEK | 121.214% |
| CellaVision AB (publ) | -56.94 Million SEK | 52.014% |
| Clinical Laserthermia Systems AB (publ) | -14.87 Million SEK | -83.666% |
| Chordate Medical Holding AB (publ) | -8.45 Million SEK | -223.162% |
| C-Rad AB (publ) | -127.6 Million SEK | 78.586% |
| Duearity AB (publ) | 10.23 Million SEK | 367.071% |
| Dignitana AB (publ) | 13.07 Million SEK | 308.947% |
| Episurf Medical AB (publ) | -52.7 Million SEK | 48.152% |
| Getinge AB (publ) | 5.4 Billion SEK | 100.505% |
| Scandinavian Real Heart AB (Publ) | -35.05 Million SEK | 22.05% |
| Iconovo AB (publ) | -10.75 Million SEK | -154.051% |
| Integrum AB (publ) | -10.47 Million SEK | -160.811% |
| Luxbright AB (publ) | -13.83 Million SEK | -97.521% |
| Mentice AB (publ) | -49.56 Million SEK | 44.871% |
| OssDsign AB (publ) | -162.78 Million SEK | 83.215% |
| Paxman AB (publ) | -11.41 Million SEK | -139.453% |
| Promimic AB (publ) | -50.32 Million SEK | 45.703% |
| Qlife Holding AB (publ) | 19.07 Million SEK | 243.283% |
| ScandiDos AB (publ) | -1.53 Million SEK | -1684.716% |
| Sectra AB (publ) | -772.85 Million SEK | 96.465% |
| Sedana Medical AB (publ) | -226.87 Million SEK | 87.956% |
| Senzime AB (publ) | -139.54 Million SEK | 80.419% |
| SpectraCure AB (publ) | -50.23 Million SEK | 45.607% |
| Stille AB | -178.5 Million SEK | 84.693% |
| Vitrolife AB (publ) | 1.22 Billion SEK | 102.225% |
| Xvivo Perfusion AB (publ) | -214.65 Million SEK | 87.27% |